Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Trial of High-dose Bendamustine, Etoposide, Cytarabine, and Melphalan (BeEAM) in the Up-front Treatment of Multiple Myeloma

NCT02416206 is registered in ClinicalTrials.gov with Northside Hospital, Inc. as lead sponsor.

NCT NCT02416206
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02416206 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Trial of High-dose Bendamustine, Etoposide, Cytarabine, and Melphalan (BeEAM) in the Up-front Treatment of Multiple Myeloma
Lead sponsor
Northside Hospital, Inc.
Phase
Phase 2
Overall status
Completed
Start date
April 27, 2015
Completion date
April 21, 2021
Enrollment
65 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

multiple myeloma